Form 4: Boundless Bio CMO Granted 230,000 Stock Options

Boundless Bio's Chief Medical Officer, Robert Doebele, was granted 230,000 stock options with a vesting schedule over 48 months.

Summary

• Robert Doebele, Chief Medical Officer of Boundless Bio, Inc. (BOLD), was granted 230,000 stock options.
• The transaction date for this grant was January 23, 2026.
• The exercise price for these stock options is $1.26 per share.
• The vesting commencement date for the options is January 1, 2026.
• The options will vest in 48 substantially equal monthly installments, with the first installment vesting on February 1, 2026, and monthly thereafter.
• The stock options have an expiration date of January 22, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a routine compensation event, generally viewed as neutral to slightly positive as it aligns management incentives with shareholder interests.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with the long-term performance and shareholder value of Boundless Bio, Inc.

Future Outlook

The stock option grant, with its 48-month vesting schedule, indicates a long-term incentive structure designed to retain and motivate the Chief Medical Officer, aligning his future performance with the company's growth over several years.

Industry Context

The grant of stock options to a key executive like the Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industry. It serves as a common form of executive compensation, aiming to attract, retain, and incentivize top talent by linking their personal financial success to the company's long-term share price performance.

Comparison to Industry Standards

• Executive stock option grants are a prevalent compensation tool across the biotech sector, including companies like Moderna, BioNTech, and Regeneron, used to align management incentives with shareholder value.
• The 48-month vesting schedule is typical for executive equity awards, providing a long-term retention mechanism consistent with industry benchmarks for key personnel.

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Medical Officer's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The stock options will begin vesting in monthly installments starting February 1, 2026, continuing over the next 48 months.

Key Dates

Keywords

Boundless Bio, BOLD, Stock Options, Executive Compensation, Insider Transaction, Form 4, Chief Medical Officer, Equity Grant